Biopharma GettyImages-1298364833.jpg
Our Work

Latham & Watkins Advises Coherus in Pricing of Public Offering of Common Stock

May 22, 2023
Bay Area team advises the commercial-stage biopharmaceutical company.

Coherus BioSciences, Inc. (Nasdaq: CHRS) has announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of US$4.25 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 1,764,705 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP represents Coherus BioSciences in the offering, with a corporate team led by Bay Area partners Ben Potter and Phillip Stoup, with Los Angeles associate Steven Schmulenson, and Bay Area associates Theresa Bloom, Chelsi DeTurk, and Rebecca Dixon. Advice was also provided on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area partner Betty Pang; on tax matters by Bay Area partner Grace Lee; on benefits matters by Bay Area partner James Metz; and on IP matters by Bay Area partner Jekkie Kim.